Month: April 2025

Press release VALLOUREC AWARDED A MAJOR CONTRACT BY KUWAIT OIL COMPANY Meudon (France), April 28, 2025 – Vallourec, a world leader in premium seamless tubular solutions, has secured a major contract to supply Oil Country Tubular Goods (OCTG) for the drilling operations of Kuwait Oil Company (KOC). This new contract represents over $130 million in potential revenue. This agreement includes the supply of carbon steel OCTG products with premium connections and proprietary steel grades, to be delivered in 2025 and 2026. Vallourec has been selected to supply the most technically advanced part of the tender in terms of grades and connections, including some of its high-torque flush premium connections. Vallourec has a historical presence in Kuwait and has been a reliable supplier to KOC, developing specific products for both its offshore and...

Ghent, April 28, 2025 – 07.30 CET – Press release / Regulated information Following the publication of its annual figures on 27 March 2025, and to announce the Annual General Meeting of 28 May 2025, ABO-Group announces today its annual report for 2024. The annual report can be consulted on the ABO-Group’s website: https://www.abo-group.eu/en/investors/shareholder-information/shareholders-meetings/. There you will find the following documents:Convocation ordinary general meeting 2025 Information for the shareholders Procuration ordinary general meeting 2025 Statutory Annual accounts 2024 Report from the commissioner on the statutory financial accounts 2024 Report from the commissioner on the consolidated financial accounts 2024About ABO-Group Environment ABO-Group, opgericht in 1995 als adviesbureau voor bodemonderzoek, is uitgegroeid...

Company announcement no. 24 / 2025Schindellegi, Switzerland – 28 April 2025 Trifork Group: Weekly report on share buyback On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. The buyback program will not be active from 9 to 15 April 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share...

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two monthsApril 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients...

Hybrid Cloud and On-Premise ERP Solution Enhances Compliance and Operational Efficiency for Vessel Management SINGAPORE, April 27, 2025 (GLOBE NEWSWIRE) — iOThree Limited (“iO3” or the “Company”) (NASDAQ: IOTR), a leading provider of maritime digital technologies including satellite connectivity and digitalization solutions in Singapore with a focus on facilitating the maritime industry towards digital transformation, today announced that its F.R.I.D.A.Y Planned Maintenance System (PMS) has received class approval from ClassNK, a leading classification society renowned for its stringent maritime standards. This certifies that the software has been approved in accordance with the functional requirements for PMS software in ClassNK’s “Guidance for the Survey and Construction of Steel Ships.” “F.R.I.D.A.Y PMS...

CHATTANOOGA, Tenn., April 27, 2025 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials and technology company today announced the appointment of Michael O’Kronley as Chief Executive Officer, effective May 19, 2025. With a strong technical foundation in engineering, Mr. O’Kronley brings over 30 years of automotive experience, including 15 years in the Lithium-ion battery and battery materials space. Most recently, Mr. O’Kronley served as Chief Executive Officer of Ascend Elements where he increased the enterprise value of the company by US$1.6 Billion in 5 years. Admiral Robert J Natter, USN Ret., Chairman of NOVONIX said “We are thrilled to welcome Mr. O’Kronley to the NOVONIX team. His professional accomplishments as well as his extensive experience in manufacturing,...

Perth, April 28, 2025 (GLOBE NEWSWIRE) — PERSEUS MINING PROCEEDS WITH DEVELOPMENT OF THE NYANZAGA GOLD PROJECT overview Perth, Western Australia/ April 28, 2025/ Perseus Mining Limited (ASX/TSX: PRU) is pleased to announce that a Final Investment Decision (FID) has been taken to develop the Nyanzaga Gold Project (NGP) in Tanzania, following an update of the NGP Feasibility Study (FS). Perseus has committed to invest approximately US$523 million (including contingency) to develop and prepare for the operation of the mine that is expected to produce first gold in Q1 2027. The NGP development will be solely financed via interest free, intercompany loans provided by Perseus from its existing cash and bullion balance of US$801 million as of 31 March 2025. In anticipation of an affirmative FID, Perseus has spent approximately US$27.5...

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled “Preclinical and translational pharmacokinetic (PK) modeling of the self-assembling and disassembling (SADA) bispecific fusion protein CD38-SADA for first-in-human (FIH) pretargeted radioimmunotherapy (PRIT)” characterizes the plasma concentrations of CD38-SADA in animal models...

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancerWOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session. ABP-102/CT-P72,...